What is Myasthenia Gravis?

Size: px

Start display at page:

Download "What is Myasthenia Gravis?"

Horace Hoover
5 years ago
Views:

1 What is Myasthenia Gravis? A presentation of the Myasthenia Gravis Association of Western Pennsylvania. 1. Myasthenia Gravis is a chronic neuromuscular disease deriving its name from Latin and Greek words meaning grave muscle weakness. The disease is characterized by abnormal weakness of voluntary muscles (those muscles controlled by will). This weakness increases with activity and decreases with periods of rest. 2. Myasthenia Gravis may affect an individual of any age or race including the newborn child. However, the disease is seen more frequently in the young adult female and in the older male. The role of heredity in MG is uncertain. 3. Myasthenia Gravis, or MG, may involve either a single muscle or a group of muscles. The muscles which control chewing, swallowing and eye movement are most often affected, followed by the muscles that control the arms and legs. The muscles used for breathing may also be affected. Weakness in these muscles may result in shortness of breath; an inability to take a deep breath; or difficulty coughing. Those MG patients who experience severe difficulty breathing usually require hospitalization. 4. To understand why the myasthenic has muscles that are weak, we need to explore how muscles function. Muscles are controlled by the nervous system. For a voluntary muscle to contract so that you can chew food, talk, breathe or walk, a message is sent from the brain along a nerve pathway to the nerve ending. 5. The nerve ending is very close to the muscle, but does not touch the muscle. The gap between the nerve ending and the muscle is called the neuromuscular junction. The message that has been sent from the brain to the nerve ending causes the release of the chemical, acetylcholine in the nerve ending. The acetylcholine carries the message to a special place on the muscle called a receptor site. Each neuromuscular junction, has many receptor sites.

2 When a sufficient number of receptor sites have been activated by acetylcholine, the muscle contracts. 6. In MG, the muscle weakness occurs because there is a reduction in the number of receptor sites at the neuromuscular junction. This destruction of receptor sites is due to an antibody. The origin o f the antibody is unknown. Because an antibody is involved in the destruction of the receptor sites, MG is classified as an autoimmune disease. To understand what the term autoimmune means, it will help to know about the body s defense system. 7. Behind the breastbone is a small gland called the thymus. Early in life the thymus gland is involved in the development of the immune system which enables the body to defend itself against illness. The exact role of the thymus in MG is unknown. 8. The thymus gland produces certain types of cells that are a vital part of the immune system. These cells stimulate the production of antibodies, which recognize foreign invaders called antigens. Normally the antibodies destroy antigens before major illness occurs. 9. In an autoimmune disease ( and there are many different kinds ), The antibodies become confused. Instead of attacking a foreign invader, the confused antibodies start attacking the body they are meant to protect. 10. In patients with MG, These confused antibodies attack the receptor sites of the neuromuscular junction. We now know that there is an % reduction in the acetylcholine receptor sites in the muscle due to the action of confused antibodies. The rate of destruction of the receptor sites is greater than the replacement of the receptor sites. Acetylcholine, therefore, does not reach enough receptor sites to cause strong muscle contractions. This leads to muscle weakness. 11. In attempting to identify the source of muscle weakness, the patient will undergo a neurological examination that includes testing of muscle strength. 12. If the doctor suspects that the patient might have Myasthenia Gravis, he may do an edrophonium, or Tensilon, test. Special medication is injected into the vein. Muscle strength will be tested before and after the medication is injected. An improvement in muscle strength provides strong support for a diagnosis of Myasthenia Gravis.

3 13. Another test that may be done to confirm the diagnosis of MG involves a repeated stimulation of a nerve, resulting in a particular type of muscle response. 14. A blood sample may also be drawn to determine the presence of the confused antibody. In 90% of MG patients, there is an elevation of this antibody. 15. While there is no known cure for Myasthenia Gravis, it can be treated in a variety of ways. These treatments include medication, plasmapheresis, and thymectomy. 16. The most frequently used treatment is medication. The drugs most commonly used today are anticholinesterase agents such as Mestinon, corticosteroid drugs such as Prednisone, and other immunosuppressive agents such as Imuran and CellCept. 17. Another form of treatment is plasmapheresis which removes the confused antibodies from the plasma portion of the blood. The striking improvement in strength following plasmapheresis is shortlived due to the continuing formation of the antibodies; therefore, the process of plasmapheresis will have to be repeated. 18. Another treatment for MG is thymectomy, the surgical removal of the thymus gland. Thymectomy may lessen the severity of myasthenic symptoms. The degree to which the symptoms are lessened differs with each patient. 19. The outlook for Myasthenia Gravis patients varies. The treatment does not completely halt the disease but does improve the symptoms. In some cases, the disease may go into remission in which case the symptoms disappear and no treatment is necessary. 20. The doctor will determine which type of treatment is best for the patient. Treatment of Myasthenia Gravis requires very careful attention to the prescribed therapy. There must be a good working relationship between the patient and the health care team. Myasthenia Gravis, though not curable by any known method, is controllable, allowing most patients to lead nearly full and productive lives.

4 Myasthenia Gravis Association of Western Pennsylvania Education Committee Elizabeth Noroian, R.N., PhD Series editor Susan Kristine, R.N. Joanne Scarnati, R.N., B.S.N. Judith Schrecker, R.N. Joanne Condi, R.N., M.N. Holly DeChancie, R.N., M.N. Acknowledgements Made possible in part by grants from: The Aggie Pallan Memorial Fund W.I.Patterson Charitable Fund Graphics Jeff McMunn and Gateway Studios The Myasthenia Gravis Association of W. Pa. Inc.: Patricia Ann Buck, M.S.W. Sylvia E. Danehy, R.N., B.S.N. Judith M. Schiffbauer, M.S.W. Medical Advisory Board Robert P.Blume, M.D. Guy R. Corsello, M.D. Pearl McNall, M.D. Thomas J. Nasca, M.D. Thomas L. Ulicny, M.D. Creamer, Inc. Richard J. Weber Ruth Raynovich A United Way Member Agency Copywright 1984

5 Myasthenia Gravis Association of Western Pennsylvania, Inc. 490 East North Avenue #410 Pittsburgh, PA A copy of the official registration and financial information of The Myasthenia Gravis Association may be obtained from the Dept. of State by calling toll-free, within Pennsylvania, Registration does not imply endorsement.

Myasthenia gravis. Page 1 of 7

Myasthenia gravis. Page 1 of 7 Myasthenia gravis What is myasthenia gravis? Myasthenia gravis (sometimes abbreviated to MG) is a chronic, autoimmune condition that causes muscle weakness and excessive muscle fatigue. It is rare, affecting